

Attorney Docket No.: PB60825USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of: Heightman *et al.*

Confirmation No.: 2093

Serial No.: 10/599,636

Group Art Unit: *(not yet assigned)*

Filing Date: October 4, 2006

Examiner: *(not yet assigned)*For: TETRAHYDROBENZAZEPINES AS HISTAMINE H₃ RECEPTOR LIGANDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Sir:

In response to the Notification of Missing Requirements mailed May 31, 2007, Applicants initiated a discussion with Barbara Campbell of the Office of PCT Operations. The USPTO had noted a discrepancy in the title on the Declaration with the title of the International Application. Ms. Campbell acknowledged that the change in title could be traced back to the priority application and that a new Declaration would not be necessary.

Applicants also respectfully submit that the application does not include any nucleotide or amino acid sequences. Accordingly, Applicants do not believe the submission of a Sequence Listing according to 37 CFR §§1.821-1.825 is required in the instant case. Therefore, Applicants respectfully request that the requirements for submission related to sequence listings be withdrawn and the application be passed to the Examiner Group for review.

In accordance with USPTO requirements, a copy of the Notification of Missing Requirements is attached. The Office is invited to contact the undersigned at (919) 483-1577 to discuss this matter further, if desired.

Respectfully submitted

Date: 11 June 2007

Bonnie L. Deppenbrock
Bonnie L. Deppenbrock
Attorney for Applicants
Registration No. 28,209

Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Phone: (919) 483-1577
Facsimile: (919) 483-7988

I hereby certify that this correspondence is being facsimile
transmitted to (571) 270-9841 on June 11, 2007.

Rebecca Kerney
Rebecca Kerney

1 of 1